GSK plc GSK announced that it has entered into a definitive agreement to acquire California-based biotech RAPT Therapeutics ...

GSK agreed to acquire Rapt Therapeutics for $2.2 billion on Tuesday, a move that ...

GSK plc to acquire RAPT Therapeutics Inc. for $58.00 per share, with an estimated upfront investment of $1.9 billion.

The acquisition will strengthen GSK’s immunology pipeline, which is a key area of focus for the pharma company.

GSK entered into a definitive agreement to acquire RAPT Therapeutics, including RAPT’s long-acting anti-immunoglobulin E (IgE ...

RAPT Therapeutics shares surged after GSK agreed to acquire the biotech for $2.2 billion, adding a promising food allergy ...

GSK has agreed to pay $58 per RAPT share, with an upfront payment of $1.9 billion, that will give it global rights to ...

GSK has agreed to acquire RAPT Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing novel ...

South Korean biotech Alteogen (Kosdaq: 196170) has signed an exclusive license agreement with Tesaro, a unit of GSK (LSE: GSK ...

GSK noted recent deals as source of fresh revenues amid patent expiries and an AI-driven boost to drug discovery.